Jump to Main Content
Cross-protective Salmonella vaccine reduces cecal and splenic colonization of multidrug-resistant Salmonella enterica serovar Heidelberg
- Bearson, Shawn M.D., Bearson, Bradley L., Sylte, Matthew J., Looft, Torey, Kogut, Michael H., Cai, Guohong
- Vaccine 2018
- Salmonella Heidelberg, Salmonella Typhimurium, cecum, cross immunity, food animals, food safety, gene expression regulation, genes, inflammation, leukocytes, morbidity, mortality, multiple drug resistance, pathogens, serotypes, spleen, swine, transcription (genetics), turkeys, vaccination, vaccines
- Salmonella vaccine strategies for food-producing animals have typically focused on a specific serovar that either causes production losses due to morbidity/mortality or is an important food safety pathogen for a particular food commodity. The Salmonella enterica serovar Typhimurium BBS 866 vaccine strain was designed to reduce serovar specificity to provide cross-protection against diverse Salmonella serovars, thereby broadening its applicability for multiple animal and poultry species. We reported cross-protection of the BBS 866 vaccine in swine [Vaccine 34:1241–6]. In the current study, we extend the efficacy of the Salmonella vaccine to a poultry commodity by revealing significant reduction of multidrug-resistant Salmonella enterica serovar Heidelberg colonization of the cecum and systemic dissemination to the spleen in BBS 866-vaccinated turkeys. Transcriptional analysis of whole blood from BBS 866-vaccinated turkeys revealed down-regulation of metabolic and immune genes (KCNAB1, ACOD1, GPR17, ADOR2AB, and IL-17RD), suggesting limited leukocyte activation without an overt peripheral inflammatory response to vaccination.